Skip to content

Press Releases

Aug 27, 2018
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study

—  Bempedoic Acid / Ezetimibe Combo Pill Achieved an Additional 35% LDL-C Lowering in Patients on Maximally Tolerated Statins  — —  35% LDL-C Lowering Provides Potential for More Than 6 Million U.S. Patients to Reach LDL-C Levels of 70 mg/dL  — —  Bempedoic Acid / Ezetimibe Combo Pill Appeared to

Aug 25, 2018
Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress

— Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background of Maximally Tolerated Statins — — Study 1 (CLEAR Harmony) Provided the Largest Evidence to Date that Bempedoic Acid Is Safe when Added on to Maximally Tolerated Statins — — Bempedoic Acid Provides Additional Oral

Aug 10, 2018
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich. , Aug. 10, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol

Aug 02, 2018
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results

ANN ARBOR, Mich. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol

Jul 03, 2018
Esperion to Host Analyst and Investor Day Event on July 10

ANN ARBOR, Mich. , July 03, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol

Jun 12, 2018
Esperion Announces Late-Breaking Oral Presentation of Full Study 4 Results (1002-048) at the International Symposium on Atherosclerosis
— Simultaneous Presentation of Full Data from 1 st Phase 3 Study at ISA and Publication in the Journal Atherosclerosis — ANN ARBOR, Mich., June 12, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the full Phase 3 results from Study 4 (1002-048, also known as CLEAR Tranquility)
May 30, 2018
Esperion to Participate in Fireside Chat at the Jefferies 2018 Global Healthcare Conference
ANN ARBOR, Mich., May 30, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
May 29, 2018
Esperion Announces the Appointment of Jay P. Shepard to Board of Directors
ANN ARBOR, Mich., May 29, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
May 25, 2018
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., May 25, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
May 23, 2018
Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint
— Study 3 Achieves Additional 26% LDL-C Lowering on Background of Maximally Tolerated LDL-C Lowering Therapy in Patients Considered Statin Intolerant — — Additional hsCRP Reduction of 25% — — Cumulative Phase 2 / Phase 3 Demonstrates Broad Efficacy as well as Safety and Tolerability — — Conference
May 22, 2018
Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
ANN ARBOR, Mich., May 22, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
May 10, 2018
Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference
ANN ARBOR, Mich., May 10, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
May 04, 2018
Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference
ANN ARBOR, Mich., May 04, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
May 02, 2018
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results
ANN ARBOR, Mich., May 02, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
May 02, 2018
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid
— Met Primary Endpoint of Safety and Tolerability in Largest and Longest Duration  Study — — Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background Maximally Tolerated Statin Therapy —  — Additional hsCRP Reduction of 22% on Background Maximally Tolerated Statin Therapy —